News / Taiwan / economic_daily
Anji Pharma Advances SBMA Drug Candidate to Phase 3 Trials in the US
Health Technology · Biotechnology · economic_daily · 2026-10-04
7754
Anji Pharma has received clearance from the US FDA to initiate Phase 3 clinical trials for its SBMA treatment, AJ201, marking a key milestone for international licensing.
What Happened
Clinical Milestone: Anji Pharma announced that its proprietary drug candidate AJ201 for Spinal and Bulbar Muscular Atrophy (SBMA) has passed the US FDA's 30-day review period, allowing the company to proceed with Phase 3 clinical trials.
Strategic Value: Advancing to Phase 3 represents a critical step toward market entry, providing clearer timelines and concrete data for international pharmaceutical companies evaluating potential partnerships.
Licensing Strategy: The company intends to leverage this progress to accelerate international licensing negotiations, aiming to secure favorable terms while maintaining global intellectual property rights.
Market Need: SBMA is a rare genetic neurodegenerative condition with no currently approved effective treatments, and experts believe the patient population is significantly underdiagnosed.